Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The target is a specific genomic DNA sequence located at the 5' splice site (donor site) of intron 50 in the human DMD gene. This site is critical for the correct recognition and splicing of exon 50 into the mature dystrophin mRNA. In therapeutic development for Duchenne Muscular Dystrophy (DMD), this DNA sequence is targeted by base-editing technologies to modify the splice signal and induce the skipping of exon 50. By bypassing exon 50 during splicing, the reading frame of the DMD gene can be restored in patients with specific out-of-frame deletions, such as those lacking exon 51 or exons 51-53. This approach, exemplified by the experimental drug GEN6050, aims to produce a truncated but functional dystrophin protein. Unlike antisense oligonucleotides that target RNA and require chronic administration, DNA-level editing at this site offers the potential for a permanent, one-time therapeutic correction.
Base editing of the DNA at the 5' splice site of intron 50 to disrupt the donor splice signal and induce exon 50 skipping
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA at the intronic IVS50 5' splice site of the human DMD gene (DMD IVS50 5'SS).